InvestWiser

Cantargia AB

CANTANasdaq StockholmHealthcareMarket value 361 m SEK
1.28SEK −2.4%
last day · Price as of 18 November 2026

The answer first

Does Cantargia beat the market?

No, Cantargia has not beaten the market over the last year.

Cantargia−62.7%Stockholm (OMXSGI)+17.6%
  • The ranking · Quality, value and trend combined

    Better than 78% of Nordic stocks

    • Quality96
    • Value94
    • Trend3

    No. 28 of 195 in healthcare

  • Expectations in the price

    Low expectations

    For the share to return about 9% a year from today's price, it is enough that the cash Cantargia keeps shrinks about 31% a year for 10 years.

Max for seven days

Follow Cantargia with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Cantargia

From today, at a price of 1.28 SEK. Write why you follow Cantargia, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Cantargia

Your first answer is free, no account needed.

Do you own Cantargia, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Cantargia and a few more. Free, no card.

Past year against the exchange and Super Stock
Cantargia−62.7%Stockholm (OMXSGI)+17.6%Super Stock+44.6%
17 November 202518 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Cantargia has fallen 62.7% over the past year, including dividends.
  • Overall, Cantargia ranks better than 78% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 94.1%. The price is 97.8% below its peak now.

What do analysts think of Cantargia?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

78

Quality, value and trend together. Better than 78% of Nordic stocks.

No. 28 of 195 in healthcare

Quality96
The company · Fundamentals: the accounts

High A solid company: it earns well on its money and has healthy finances.

No. 16 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.00
  • Asset turnoverSales divided by everything the company owns1.03
  • Return on equityProfit divided by equity+63.4%
  • Cash conversionOperating cash flow divided by profit0.98

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value94
The price · Valuation: the multiples

High Low price: you pay little for what the company earns and owns.

No. 7 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equity1.2
  • P/SPrice divided by sales1.0
  • P/EPrice divided by earnings1.8
  • P/CFPrice divided by operating cash flow1.8

The ranking is built on P/E, P/B and P/S.

Trend3
The share price · Technical: the price trend

Low Headwind in the share price: it has done worse than most over the last year.

No. 183 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months−38.7%
  • 6 months−57.9%
  • 9 months−74.7%
  • 12 months−62.7%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
−4.6%
3 years, per year
−29.2%
5 years, per year
−38.0%
10 years, per year
−15.9%
Largest fall, 3 years
−94.1%
From a peak to the bottom
From the peak now
−97.8%
How far the price is from the peak
Volatility, 1 year
66.2%
How much the price swings over a year
Beta, 1 year
0.93
How much the price moves when the market moves

Return with dividends reinvested.

The funds that own Cantargia

5 funds we follow own Cantargia. The share is how much of the fund the stock makes up.

  • Sweden5

From the funds' latest known holdings.

About Cantargia

Cantargia AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 22 employees.

Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an monoclonal antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in phase 1 clinical trial for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also develops CANxx, an IL1RAP-based antibody platform.

See the full analysis of Cantargia.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market